Tetrabenazine
- Generic Name
- Tetrabenazine
- Brand Names
- Nitoman, Xenazine
- Drug Type
- Small Molecule
- Chemical Formula
- C19H27NO3
- CAS Number
- 58-46-8
- Unique Ingredient Identifier
- Z9O08YRN8O
- Background
A drug formerly used as an antipsychotic but now used primarily in the symptomatic treatment of various hyperkinetic disorders. It is a monoamine depletor and used as symptomatic treatment of chorea associated with Huntington's disease. FDA approved on August 15, 2008.
- Indication
Treatment of hyperkinetic movement disorders like chorea in Huntington's disease, hemiballismus, senile chorea, Tourette syndrome and other tic disorders, and tardive dyskinesia
- Associated Conditions
- Gilles de la Tourette's Syndrome, Hemiballismus, Huntington's Disease (HD), Tardive Dyskinesia (TD), Senile chorea
- Associated Therapies
- -
Neuroleptic and Huntington Disease Comparison of : Olanzapine, la Tetrabenazine and Tiapride
Phase 3
Completed
- Conditions
- Huntington Disease
- Interventions
- First Posted Date
- 2008-03-11
- Last Posted Date
- 2018-01-19
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 180
- Registration Number
- NCT00632645
- Locations
- 🇫🇷
CHU Henri Mondor, Creteil, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath